DALLAS / Nov 07, 2023 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the third quarter ended September 30, 2023.
“In the midst of industry disruption associated with Medicare reimbursement uncertainty, labor pressures and the shift to Medicare Advantage, we continue to deliver on our mission of providing exceptional care to our patients,” said Enhabit’s President and Chief Executive Officer, Barb Jacobsmeyer. “We are winning the war for labor as demonstrated by our recruitment of an additional 166 net new nursing hires in the third quarter, and payors are increasingly receptive to our value proposition given our hospital readmission rates which are 20% better than the national average. Some payors are recognizing the variation of quality results within the industry and are willing to pay for access to high-quality providers like Enhabit.”
QUARTERLY PERFORMANCE - CONSOLIDATED
RECENT COMPANY HIGHLIGHTS
FINANCIAL RESULTS
Consolidated
($ in millions, except per share data) | Q3 | '23 vs. '22 | ||||||||||
| 2023 | 2022 | ||||||||||
Home health net service revenue | $ | 210.9 | $ | 216.3 | (2.5) % | |||||||
Hospice net service revenue |
| 47.4 |
| 49.4 | (4.0) % | |||||||
Total net service revenue | $ | 258.3 | $ | 265.7 | (2.8) % | |||||||
| % of Revenue | % of Revenue |
| |||||||||
Cost of services | 51.9 % |
| (134.0) | 49.8 % |
| (132.3) | 1.3 % | |||||
Gross margin | 48.1 % |
| 124.3 | 50.2 % |
| 133.4 | (6.8) % | |||||
General & administrative expenses | 39.1 % |
| (101.0) | 38.2 % |
| (101.4) | (0.4) % | |||||
Total operating expenses | 91.0 % |
| (235.0) | 88.0 % |
| (233.7) | 0.6 % | |||||
Other income |
| 0.1 |
| — |
| |||||||
Equity earnings / noncontrolling interest |
| (0.2) |
| (0.3) |
| |||||||
Adjusted EBITDA | $ | 23.2 | $ | 31.7 | (26.8) % | |||||||
Adjusted EBITDA margin |
| 9.0 % |
| 11.9 % |
| |||||||
Net (Loss) Income Attributable to Enhabit, Inc. | $ | (2.4) | $ | 8.6 | (127.9) % | |||||||
Reported Diluted EPS | $ | (0.05) | $ | 0.17 | (128.9) % | |||||||
Adjusted Diluted EPS | $ | 0.03 | $ | 0.19 | (84.2) % | |||||||
The continued shift to more non-episodic admissions in home health impacted consolidated revenue and Adjusted EBITDA by approximately $8 million, net of the impact from improved pricing of payor innovation contracts.
SEGMENT RESULTS
Home health
($ in millions) | Q3 | '23 vs. '22 | |||
|
| 2023 |
| 2022 | |
Net service revenue | $ | 210.9 | $ | 216.3 | (2.5)% |
Cost of services |
| 110.0 |
| 109.6 | 0.4% |
Gross margin |
| 47.8 % |
| 49.3 % |
|
General & administrative expenses |
| 59.0 |
| 61.9 | (4.7)% |
Other income |
| (0.1) |
| — |
|
Equity earnings / noncontrolling interest |
| 0.2 |
| 0.2 | —% |
Adjusted EBITDA | $ | 41.8 | $ | 44.6 | (6.3)% |
% Adj. EBITDA margin |
| 19.8 % |
| 20.6 % |
|
Operational metrics (Actual Amounts) |
|
|
| ||
Starts of care |
|
|
| ||
Episodic admissions |
| 31,490 |
| 35,487 | (11.3)% |
Non-episodic admissions |
| 19,033 |
| 14,252 | 33.5% |
Total admissions |
| 50,523 |
| 49,739 | 1.6% |
Episodic recertifications |
| 23,290 |
| 25,821 | (9.8)% |
Non-episodic recertifications |
| 9,442 |
| 6,541 | 44.4% |
Total recertifications |
| 32,732 |
| 32,362 | 1.1% |
Total starts of care |
| 83,255 |
| 82,101 | 1.4% |
Completed episodes |
| 53,484 |
| 60,396 | (11.4)% |
Revenue per episode | $ | 3,128 | $ | 3,009 | 4.0% |
Visits per episode |
| 14.9 |
| 14.9 | — % |
Total visits |
| 1,162,144 |
| 1,175,002 | (1.1) % |
Non-episodic visits |
| 365,071 |
| 272,282 | 34.1 % |
Cost per visit | $ | 93 | $ | 92 | 1.1 % |
The year-over-year decrease in revenue was due primarily to the continued payor mix shift to more non-episodic admissions. Non-episodic admissions grew 33.5% in the quarter, driving total admission growth of 1.6% year over year. Revenue per episode increased year over year primarily due to changes in our estimated recoverability of net service revenue.
Revenue and Adjusted EBITDA decreased $8 million in Q3 due to the continued payor mix shift to more non-episodic admissions. Cost per visit increased 1.1% year over year primarily due to merit and market rate increases for clinical staff, partially offset by improved nursing productivity.
Hospice
($ in millions) | Q3 | '23 vs. '22 | |||
|
| 2023 |
| 2022 | |
Net service revenue | $ | 47.4 | $ | 49.4 | (4.0)% |
Cost of services |
| 24.0 |
| 22.7 | 5.7% |
Gross margin |
| 49.4 % |
| 54.0 % |
|
General & administrative expenses |
| 15.7 |
| 17.3 | (9.2)% |
Equity earnings / noncontrolling interest |
| — |
| 0.1 |
|
Adjusted EBITDA | $ | 7.7 | $ | 9.3 | (17.2)% |
% Adj. EBITDA margin |
| 16.2 % |
| 18.8 % |
|
Operational metrics (Actual Amounts) |
|
|
| ||
Total admissions |
| 2,882 |
| 2,982 | (3.4)% |
Patient days |
| 311,719 |
| 320,732 | (2.8)% |
Discharged average length of stay |
| 107 |
| 103 | 3.9% |
Average daily census |
| 3,388 |
| 3,486 | (2.8)% |
Revenue per day | $ | 152 | $ | 154 | (1.3)% |
Cost per day | $ | 77 | $ | 71 | 8.5% |
Net service revenue decreased year over year primarily due to a decrease in patient days.
Adjusted EBITDA decreased year over year primarily due to higher cost of services resulting from increased labor costs. Cost per day increased year over year primarily due to increased labor costs resulting from the implementation of the new case management model, including costs associated with dedicated on-call and triage nurses.
CREDIT AGREEMENT AMENDMENT
On November 3, 2023, Enhabit entered into an amendment to its credit agreement with its bank group. The amendment provided for additional cushion to the Company’s financial covenants through March 31, 2025. The amendment also included a permanent reduction in the revolver commitment from $350 million to $220 million. The Company expects to realize a reduction in commitment fees of $0.3 million per year as a result of the commitment reduction.
“The covenant levels requested and received were done out of an abundance of caution as we continue to operate in an industry with shifting dynamics in payor sources and reimbursement,” said Enhabit’s Chief Financial Officer, Crissy Carlisle. “Given our cash on hand and availability under our revolver, we believe we have adequate liquidity to service our debt and fund operations.”
GUIDANCE
The Company revised its full-year 2023 guidance as follows:
($ in millions, except per share data) | 2023 | 2023 | |
Net Service Revenue | $1,057 to $1,065 | $1,044 to $1,048 |
|
Adjusted EBITDA | $100 to $107 | $93 to $98 |
|
Adjusted EPS | $0.28 to $0.46 | $0.09 to $0.31 |
|
For additional considerations regarding the Company’s 2023 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com.
CONFERENCE CALL INFORMATION
The Company will host an investor conference call at 10 AM Eastern Time on November 8, 2023 to discuss its results for the third quarter of 2023. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/530971935. Following the call, a replay will be available at Enhabit’s investor website.
ABOUT ENHABIT HOME HEALTH & HOSPICE
Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 255 home health locations and 109 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.
OTHER INFORMATION
Note regarding presentation and reconciliation of non-GAAP financial measures
The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, and Adjusted free cash flow. See “Reconciliations of Non-GAAP Financial Measures” for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies.
The Company is unable to reconcile the guidance for Adjusted EBITDA and Adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information.
Note regarding presentation of same-store comparisons
The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.
Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Unaudited) | |||||||||||||
| Three Months Ended September 30, |
| Nine Months Ended September 30, | ||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||
| ($ in millions, except per share data) | ||||||||||||
Net service revenue | $ | 258.3 |
|
| $ | 265.7 |
| $ | 785.7 |
|
| $ | 808.0 |
Cost of service, excluding depreciation and amortization |
| 134.0 |
|
|
| 132.3 |
|
| 402.1 |
|
|
| 392.3 |
General and administrative expenses |
| 108.8 |
|
|
| 107.5 |
|
| 327.1 |
|
|
| 310.4 |
Depreciation and amortization |
| 7.7 |
|
|
| 8.0 |
|
| 23.2 |
|
|
| 24.7 |
Impairment of goodwill |
| — |
|
|
| — |
|
| 85.8 |
|
|
| — |
Operating income (loss) |
| 7.8 |
|
|
| 17.9 |
|
| (52.5 | ) |
|
| 80.6 |
Interest expense and amortization of debt discounts and fees |
| 10.9 |
|
|
| 6.2 |
|
| 30.7 |
|
|
| 6.3 |
Other (income) expense |
| (0.1 | ) |
|
| — |
|
| (0.2 | ) |
|
| — |
(Loss) income before income taxes and noncontrolling interests |
| (3.0 | ) |
|
| 11.7 |
|
| (83.0 | ) |
|
| 74.3 |
Income tax (benefit) expense |
| (0.8 | ) |
|
| 2.8 |
|
| (9.9 | ) |
|
| 17.9 |
Net (loss) income |
| (2.2 | ) |
|
| 8.9 |
|
| (73.1 | ) |
|
| 56.4 |
Less: Net income attributable to noncontrolling interests |
| 0.2 |
|
|
| 0.3 |
|
| 1.0 |
|
|
| 1.6 |
Net (loss) income attributable to Enhabit, Inc. | $ | (2.4 | ) |
| $ | 8.6 |
| $ | (74.1 | ) |
| $ | 54.8 |
|
|
|
|
|
|
|
| ||||||
Weighted average common shares outstanding: |
|
|
|
|
|
|
| ||||||
Basic |
| 49.9 |
|
|
| 49.6 |
|
| 49.8 |
|
|
| 49.6 |
Diluted |
| 49.9 |
|
|
| 49.7 |
|
| 49.8 |
|
|
| 49.7 |
|
|
|
|
|
|
|
| ||||||
(Loss) earnings per common share: |
|
|
|
|
|
|
| ||||||
Basic (loss) earnings per share attributable to Enhabit, Inc. common stockholders | $ | (0.05 | ) |
| $ | 0.17 |
| $ | (1.48 | ) |
| $ | 1.10 |
Diluted (loss) earnings per share attributable to Enhabit, Inc. common stockholders | $ | (0.05 | ) |
| $ | 0.17 |
| $ | (1.48 | ) |
| $ | 1.10 |
Enhabit, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited) | |||||
| September 30, 2023 |
| December 31, 2022 | ||
| ($ in millions) | ||||
Assets |
|
|
| ||
Current assets: |
|
|
| ||
Cash and cash equivalents | $ | 31.6 |
| $ | 22.9 |
Restricted cash |
| 3.6 |
|
| 4.3 |
Accounts receivable |
| 167.8 |
|
| 149.6 |
Income tax receivable |
| 2.7 |
|
| 11.4 |
Prepaid expenses and other current assets |
| 12.1 |
|
| 23.6 |
Total current assets |
| 217.8 |
|
| 211.8 |
Property and equipment, net |
| 20.1 |
|
| 20.4 |
Operating lease right-of-use assets |
| 60.0 |
|
| 42.0 |
Goodwill |
| 1,061.7 |
|
| 1,144.8 |
Intangible assets, net |
| 85.9 |
|
| 102.6 |
Other long-term assets |
| 5.4 |
|
| 5.2 |
Total assets | $ | 1,450.9 |
| $ | 1,526.8 |
Liabilities and Stockholders’ Equity |
|
|
| ||
Current liabilities: |
|
|
| ||
Current portion of long-term debt | $ | 22.6 |
| $ | 23.1 |
Current operating lease liabilities |
| 12.7 |
|
| 14.0 |
Accounts payable |
| 6.0 |
|
| 3.8 |
Accrued payroll |
| 48.6 |
|
| 35.5 |
Refunds due patients and other third-party payors |
| 7.8 |
|
| 8.3 |
Accrued medical insurance |
| 8.4 |
|
| 7.5 |
Other current liabilities |
| 36.9 |
|
| 40.7 |
Total current liabilities |
| 143.0 |
|
| 132.9 |
Long-term debt, net of current portion |
| 535.8 |
|
| 560.0 |
Long-term operating lease liabilities |
| 47.0 |
|
| 28.1 |
Deferred income tax liabilities |
| 16.3 |
|
| 28.6 |
Other long-term liabilities |
| — |
|
| 1.9 |
|
| 742.1 |
|
| 751.5 |
Commitments and contingencies |
|
|
| ||
Redeemable noncontrolling interests |
| 5.0 |
|
| 5.2 |
Stockholders’ equity: |
|
|
| ||
Enhabit, Inc. stockholders’ equity |
| 676.6 |
|
| 741.7 |
Noncontrolling interests |
| 27.2 |
|
| 28.4 |
Total stockholders’ equity |
| 703.8 |
|
| 770.1 |
Total liabilities and stockholders’ equity | $ | 1,450.9 |
| $ | 1,526.8 |
Enhabit, Inc. and Subsidiaries Condensed Consolidated Cash Flows (Unaudited) | |||||||
| Nine Months Ended September 30, | ||||||
|
| 2023 |
|
|
| 2022 |
|
| ($ in millions) | ||||||
Cash flows from operating activities: |
|
|
| ||||
Net (loss) income | $ | (73.1 | ) |
| $ | 56.4 |
|
Adjustments to reconcile net (loss) income to net cash provided by operating activities— |
|
|
| ||||
Depreciation and amortization |
| 23.2 |
|
|
| 24.7 |
|
Amortization of debt related costs |
| 1.0 |
|
|
| 0.3 |
|
Impairment of goodwill |
| 85.8 |
|
|
| — |
|
Stock-based compensation |
| 7.2 |
|
|
| 7.1 |
|
Deferred tax benefit |
| (13.1 | ) |
|
| (2.5 | ) |
Other, net |
| 0.7 |
|
|
| — |
|
Changes in assets and liabilities, net of acquisitions— |
|
|
| ||||
Accounts receivable |
| (17.8 | ) |
|
| 16.4 |
|
Prepaid expenses and other assets |
| 19.9 |
|
|
| (22.5 | ) |
Accounts payable |
| 2.2 |
|
|
| (0.2 | ) |
Accrued payroll |
| 13.1 |
|
|
| (3.3 | ) |
Other liabilities |
| (3.6 | ) |
|
| (0.4 | ) |
Net cash provided by operating activities |
| 45.5 |
|
|
| 76.0 |
|
Cash flows from investing activities: |
|
|
| ||||
Acquisition of businesses, net of cash acquired |
| (2.8 | ) |
|
| — |
|
Purchases of property and equipment |
| (3.1 | ) |
|
| (5.3 | ) |
Additions to capitalized software costs |
| (0.5 | ) |
|
| — |
|
Other, net |
| 0.6 |
|
|
| 1.2 |
|
Net cash used in investing activities |
| (5.8 | ) |
|
| (4.1 | ) |
Cash flows from financing activities: |
|
|
| ||||
Principal borrowings on term loan |
| — |
|
|
| 400.0 |
|
Principal payments on term loan |
| (15.0 | ) |
|
| (5.0 | ) |
Principal payments on debt |
| — |
|
|
| (0.4 | ) |
Borrowings on revolving credit facility |
| — |
|
|
| 170.0 |
|
Payments on revolving credit facility |
| (10.0 | ) |
|
| — |
|
Principal payments under finance lease obligations |
| (2.6 | ) |
|
| (3.6 | ) |
Debt issuance costs |
| (1.1 | ) |
|
| — |
|
Distributions paid to noncontrolling interests of consolidated affiliates |
| (2.5 | ) |
|
| — |
|
Contributions from Encompass |
| — |
|
|
| 59.8 |
|
Distributions to Encompass |
| — |
|
|
| (654.9 | ) |
Contributions from noncontrolling interests of consolidated affiliates |
| — |
|
|
| 7.4 |
|
Other |
| (0.5 | ) |
|
| (5.3 | ) |
Net cash used in financing activities |
| (31.7 | ) |
|
| (32.0 | ) |
Increase in cash, cash equivalents, and restricted cash |
| 8.0 |
|
|
| 39.9 |
|
Cash, cash equivalents, and restricted cash at beginning of year |
| 27.2 |
|
|
| 8.0 |
|
Cash, cash equivalents, and restricted cash at end of period | $ | 35.2 |
|
| $ | 47.9 |
|
Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share | |||||||||||
| Three Months Ended September 30, |
| Nine Months Ended September 30, | ||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||
Diluted earnings per share, as reported | $ | (0.05) |
| $ | 0.17 |
| $ | (1.48) |
| $ | 1.10 |
Adjustments, net of tax: |
|
|
|
|
|
|
| ||||
Impairment of goodwill |
| — |
|
| — |
|
| 1.50 |
|
| — |
Unusual or nonrecurring items that are not typical of ongoing operations(1) |
| 0.07 |
|
| 0.02 |
|
| 0.14 |
|
| 0.11 |
Income tax adjustments(2) |
| — |
|
| — |
|
| 0.01 |
|
| — |
Adjusted diluted earnings per share(3) | $ | 0.03 |
| $ | 0.19 |
| $ | 0.16 |
| $ | 1.21 |
(1) | Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation, restructuring activities, and shareholder activism; in Q3 2022, they include one-time standalone transition costs; in YTD 2022, they include one-time standalone transition costs and costs due to Encompass strategic review. |
(2) | Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. |
(3) | Adjusted EPS may not sum due to rounding. |
Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Adjusted EBITDA to Adjusted Diluted Earnings Per Share | |||||||||||
| Three Months Ended September 30, | ||||||||||
| 2023 | ||||||||||
|
| Adjustments |
| ||||||||
| As Reported |
| Unusual or nonrecurring items that are not typical of ongoing operations |
| Income Tax Adjustments(3) |
| As Adjusted | ||||
| ($ in millions, except per share data) | ||||||||||
Adjusted EBITDA(1) | $ | 23.2 |
| $ | — |
| $ | — |
| $ | 23.2 |
Interest expense and amortization of debt discounts & fees |
| (10.9) |
|
| — |
|
| — |
|
| (10.9) |
Depreciation and amortization |
| (7.7) |
|
| — |
|
| — |
|
| (7.7) |
Unusual or nonrecurring items that are not typical of ongoing operations(2) |
| (4.9) |
|
| 4.9 |
|
| — |
|
| — |
Stock-based compensation |
| (3.1) |
|
| — |
|
| — |
|
| (3.1) |
Gain on disposal or impairment of assets |
| 0.2 |
|
| — |
|
| — |
|
| 0.2 |
Net (loss) income before income taxes, including noncontrolling interests |
| (3.2) |
|
| 4.9 |
|
| — |
|
| 1.7 |
Income tax benefit (expense) |
| 0.8 |
|
| (1.3) |
|
| 0.1 |
|
| (0.4) |
Net (loss) income attributable to Enhabit | $ | (2.4) |
| $ | 3.6 |
| $ | 0.1 |
| $ | 1.3 |
Diluted earnings per share(4) | $ | (0.05) |
| $ | 0.07 |
| $ | — |
| $ | 0.03 |
Diluted shares |
| 49.9 |
|
|
|
|
|
| 49.9 | ||
(1) | Reconciliation to GAAP provided on page 14. |
(2) | Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation, restructuring activities, and shareholder activism. |
(3) | Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. |
(4) | Diluted EPS may not sum due to rounding. |
| |||||||||||
Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Adjusted EBITDA to Adjusted Diluted Earnings Per Share | |||||||||||
| Three Months Ended September 30, | ||||||||||
| 2022 | ||||||||||
|
| Adjustments |
| ||||||||
| As Reported |
| Unusual or nonrecurring items that are not typical of ongoing operations |
| As Adjusted | ||||||
| ($ in millions, except per share data) | ||||||||||
Adjusted EBITDA(1) | $ | 31.7 |
|
| $ | — |
|
| $ | 31.7 |
|
Depreciation and amortization |
| (8.0 | ) |
|
| — |
|
|
| (8.0 | ) |
Interest expense and amortization of debt discounts & fees |
| (6.2 | ) |
|
| — |
|
|
| (6.2 | ) |
Stock-based compensation |
| (4.5 | ) |
|
| — |
|
|
| (4.5 | ) |
Unusual or nonrecurring items that are not typical of ongoing operations(2) |
| (0.9 | ) |
|
| 0.9 |
|
|
| — |
|
Loss on disposal or impairment of assets |
| (0.7 | ) |
|
| — |
|
|
| (0.7 | ) |
Income before income tax expense |
| 11.4 |
|
|
| 0.9 |
|
|
| 12.3 |
|
Provision for income tax expense |
| (2.8 | ) |
|
| (0.1 | ) |
|
| (2.9 | ) |
Net income attributable to Enhabit | $ | 8.6 |
|
| $ | 0.8 |
|
| $ | 9.4 |
|
Adjusted diluted earnings per share(3) | $ | 0.17 |
|
| $ | 0.02 |
|
| $ | 0.19 |
|
Diluted shares used in calculation |
| 49.7 |
|
|
|
|
| 49.7 |
| ||
(1) | Reconciliation to GAAP provided on page 14. |
(2) | Unusual or nonrecurring items include one-time standalone transition costs. |
(3) | Adjusted diluted EPS may not sum due to rounding. |
Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Adjusted EBITDA to Adjusted Diluted Earnings Per Share | ||||||||||||||||||
| Nine Months Ended September 30, | |||||||||||||||||
| 2023 | |||||||||||||||||
|
|
| Adjustments |
|
| |||||||||||||
| As Reported |
| Impairment of Goodwill |
| Unusual or nonrecurring items that are not typical of ongoing operations |
| Income Tax Adjustments(3) |
| As Adjusted | |||||||||
| ($ in millions, except per share data) | |||||||||||||||||
Adjusted EBITDA(1) | $ | 72.5 |
|
| $ | — |
|
| $ | — |
|
| $ | — |
| $ | 72.5 |
|
Impairment of goodwill |
| (85.8 | ) |
|
| 85.8 |
|
|
| — |
|
|
| — |
|
| — |
|
Interest expense and amortization of debt discounts & fees |
| (30.7 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
| (30.7 | ) |
Depreciation and amortization |
| (23.2 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
| (23.2 | ) |
Unusual or nonrecurring items that are not typical of ongoing operations(2) |
| (9.8 | ) |
|
| — |
|
|
| 9.8 |
|
|
| — |
|
| — |
|
Stock-based compensation |
| (7.2 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
| (7.2 | ) |
Gain on disposal or impairment of assets |
| 0.2 |
|
|
| — |
|
|
| — |
|
|
| — |
|
| 0.2 |
|
Net (loss) income before income taxes, including noncontrolling interests |
| (84.0 | ) |
|
| 85.8 |
|
|
| 9.8 |
|
|
| — |
|
| 11.6 |
|
Income tax benefit (expense) |
| 9.9 |
|
|
| (11.1 | ) |
|
| (2.9 | ) |
|
| 0.6 |
|
| (3.5 | ) |
Net (loss) income attributable to Enhabit | $ | (74.1 | ) |
| $ | 74.7 |
|
| $ | 6.9 |
|
| $ | 0.6 |
| $ | 8.1 |
|
Diluted earnings per share(4) | $ | (1.48 | ) |
| $ | 1.50 |
|
| $ | 0.14 |
|
| $ | 0.01 |
| $ | 0.16 |
|
Diluted shares |
| 49.8 |
|
|
|
|
|
|
|
|
| 49.8 |
| |||||
(1) | Reconciliation to GAAP provided on page 14. |
(2) | Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation, restructuring activities, and shareholder activism. |
(3) | Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. |
(4) | Diluted EPS may not sum due to rounding. |
Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Adjusted EBITDA to Adjusted Diluted Earnings Per Share | |||||||||||
| Nine Months Ended September 30, | ||||||||||
| 2022 | ||||||||||
|
| Adjustments |
| ||||||||
| As Reported |
| Unusual or nonrecurring items that are not typical of ongoing operations |
| As Adjusted | ||||||
| ($ in millions, except per share data) | ||||||||||
Adjusted EBITDA(1) | $ | 119.0 |
|
| $ | — |
|
| $ | 119.0 |
|
Depreciation and amortization |
| (24.7 | ) |
|
| — |
|
|
| (24.7 | ) |
Stock-based compensation |
| (7.1 | ) |
|
| — |
|
|
| (7.1 | ) |
Unusual or nonrecurring items that are not typical of ongoing operations(2) |
| (7.0 | ) |
|
| 7.0 |
|
|
| — |
|
Interest expense and amortization of debt discounts and fees |
| (6.3 | ) |
|
| — |
|
|
| (6.3 | ) |
Stock-based compensation included in overhead allocation |
| (1.1 | ) |
|
| — |
|
|
| (1.1 | ) |
Loss on disposal or impairment of assets |
| (0.1 | ) |
|
| — |
|
|
| (0.1 | ) |
Income before income tax expense |
| 72.7 |
|
|
| 7.0 |
|
|
| 79.7 |
|
Provision for income tax expense |
| (17.9 | ) |
|
| (1.6 | ) |
|
| (19.5 | ) |
Net income attributable to Enhabit | $ | 54.8 |
|
| $ | 5.4 |
|
| $ | 60.2 |
|
Adjusted diluted earnings per share(3) | $ | 1.10 |
|
| $ | 0.11 |
|
| $ | 1.21 |
|
Diluted shares used in calculation |
| 49.7 |
|
|
|
|
| 49.7 |
| ||
(1) | Reconciliation to GAAP provided on page 14. |
(2) | Unusual or nonrecurring items in 2022 include one-time standalone transition costs and costs due to Encompass strategic review. |
(3) | Adjusted diluted EPS may not sum due to rounding. |
Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Net Income to Adjusted EBITDA | |||||||||||||||
| Three Months Ended September 30, |
| Nine Months Ended September 30, | ||||||||||||
|
| 2023 |
|
|
| 2022 |
|
|
| 2023 |
|
|
| 2022 |
|
| ($ in millions) | ||||||||||||||
Net (loss) income | $ | (2.2 | ) |
| $ | 8.9 |
|
| $ | (73.1 | ) |
| $ | 56.4 |
|
Interest expense and amortization of debt discounts and fees |
| 10.9 |
|
|
| 6.2 |
|
|
| 30.7 |
|
|
| 6.3 |
|
Depreciation and amortization |
| 7.7 |
|
|
| 8.0 |
|
|
| 23.2 |
|
|
| 24.7 |
|
Unusual or nonrecurring items that are not typical of ongoing operations(1) |
| 4.9 |
|
|
| 0.9 |
|
|
| 9.8 |
|
|
| 7.0 |
|
Stock-based compensation |
| 3.1 |
|
|
| 4.5 |
|
|
| 7.2 |
|
|
| 7.1 |
|
Income tax (benefit) expense |
| (0.8 | ) |
|
| 2.8 |
|
|
| (9.9 | ) |
|
| 17.9 |
|
Net income attributable to noncontrolling interests |
| (0.2 | ) |
|
| (0.3 | ) |
|
| (1.0 | ) |
|
| (1.6 | ) |
(Gain) loss on disposal or impairment of assets |
| (0.2 | ) |
|
| 0.7 |
|
|
| (0.2 | ) |
|
| 0.1 |
|
Impairment of goodwill |
| — |
|
|
| — |
|
|
| 85.8 |
|
|
| — |
|
Stock-based compensation included in overhead allocation |
| — |
|
|
| — |
|
|
| — |
|
|
| 1.1 |
|
Adjusted EBITDA | $ | 23.2 |
|
| $ | 31.7 |
|
| $ | 72.5 |
|
| $ | 119.0 |
|
(1) | Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation, restructuring activities, and shareholder activism; in Q3 2022, they include one-time standalone transition costs; in YTD 2022, they include one-time standalone transition costs and costs due to Encompass strategic review. |
Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA | |||||||||||||||
| Three Months Ended September 30, |
| Nine Months Ended September 30, | ||||||||||||
|
| 2023 |
|
|
| 2022 |
|
|
| 2023 |
|
|
| 2022 |
|
| ($ in millions) | ||||||||||||||
Net cash provided by operating activities | $ | 6.3 |
|
| $ | 1.0 |
|
| $ | 45.5 |
|
| $ | 76.0 |
|
Interest expense, excluding amortization of debt discounts and fees |
| 10.7 |
|
|
| 6.2 |
|
|
| 30.3 |
|
|
| 6.3 |
|
Unusual or nonrecurring items that are not typical of ongoing operations(1) |
| 4.9 |
|
|
| 0.9 |
|
|
| 9.8 |
|
|
| 7.0 |
|
Current portion of income tax expense |
| 1.3 |
|
|
| 3.9 |
|
|
| 3.2 |
|
|
| 20.4 |
|
Net income attributable to noncontrolling interests in continuing operations |
| (0.2 | ) |
|
| (0.3 | ) |
|
| (1.0 | ) |
|
| (1.6 | ) |
Other |
| 0.2 |
|
|
| (0.3 | ) |
|
| (0.3 | ) |
|
| (0.2 | ) |
Change in assets and liabilities, excluding derivative instruments |
| — |
|
|
| 20.3 |
|
|
| (15.0 | ) |
|
| 10.0 |
|
Stock-based compensation included in overhead allocation |
| — |
|
|
| — |
|
|
| — |
|
|
| 1.1 |
|
Adjusted EBITDA | $ | 23.2 |
|
| $ | 31.7 |
|
| $ | 72.5 |
|
| $ | 119.0 |
|
(1) | Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation, restructuring activities, and shareholder activism; in Q3 2022, they include one-time standalone transition costs; in YTD 2022, they include one-time standalone transition costs and costs due to Encompass strategic review. |
Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow | |||||||||||||||
| Three Months Ended September 30, |
| Nine Months Ended September 30, | ||||||||||||
|
| 2023 |
|
|
| 2022 |
|
|
| 2023 |
|
|
| 2022 |
|
| ($ in millions) | ||||||||||||||
Net cash provided by operating activities | $ | 6.3 |
|
| $ | 1.0 |
|
| $ | 45.5 |
|
| $ | 76.0 |
|
Unusual or nonrecurring items that are not typical of ongoing operations(1) |
| 4.9 |
|
|
| 0.9 |
|
|
| 9.8 |
|
|
| 7.0 |
|
Capital expenditures for maintenance |
| (1.9 | ) |
|
| (0.5 | ) |
|
| (3.6 | ) |
|
| (3.1 | ) |
Other working capital adjustments |
| (0.7 | ) |
|
| 0.9 |
|
|
| (1.7 | ) |
|
| — |
|
Distributions paid to noncontrolling interests of consolidated affiliates |
| — |
|
|
| (0.2 | ) |
|
| (2.5 | ) |
|
| (0.9 | ) |
Stock-based compensation included in overhead allocation |
| — |
|
|
| — |
|
|
| — |
|
|
| 1.1 |
|
Adjusted free cash flow | $ | 8.6 |
|
| $ | 2.1 |
|
| $ | 47.5 |
|
| $ | 80.1 |
|
(1) | Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation, restructuring activities, and shareholder activism; in Q3 2022, they include one-time standalone transition costs; in YTD 2022, they include one-time standalone transition costs and costs due to Encompass strategic review. |
Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Gross Margin to Adjusted EBITDA Margin | |||||||||||
| Three Months Ended September 30, |
| Nine Months Ended September 30, | ||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||
|
| ||||||||||
Gross margin as a percentage of revenue | 48.1 | % |
| 50.2 | % |
| 48.8 | % |
| 51.4 | % |
General and administrative expenses | (42.1 | )% |
| (40.5 | )% |
| (41.6 | )% |
| (38.4 | )% |
Unusual or nonrecurring items that are not typical of ongoing operations(1) | 1.9 | % |
| 0.3 | % |
| 1.2 | % |
| 0.9 | % |
Stock-based compensation | 1.2 | % |
| 1.7 | % |
| 0.9 | % |
| 1.0 | % |
Noncontrolling interests | (0.1 | )% |
| — | % |
| (0.1 | )% |
| (0.2 | )% |
(Gain) loss on disposal or impairment of assets | — | % |
| 0.2 | % |
| — | % |
| — | % |
Adjusted EBITDA Margin | 9.0 | % |
| 11.9 | % |
| 9.2 | % |
| 14.7 | % |
(1) | Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation, restructuring activities, and shareholder activism; in Q3 2022, they include one-time standalone transition costs; in YTD 2022, they include one-time standalone transition costs and costs due to Encompass strategic review. |
FORWARD-LOOKING STATEMENTS
Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Enhabit include, but are not limited to, our ability to execute on our strategic plans, regulatory and other developments impacting the markets for our services, changes in reimbursement rates, general economic conditions, our ability to attract and retain key management personnel and healthcare professionals, potential disruptions or breaches of our or our vendors’ information systems, the outcome of litigation, our ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures, our ability to control costs, particularly labor and employee benefit costs, and that our review of strategic alternatives will result in our pursuing any strategic transaction, or that we will successfully consummate any particular strategic transaction on attractive terms or at all. Our annual reports on Form 10-K and quarterly reports on Form 10-Q, each of which can be found on the Company’s website at http://investors.ehab.com and the SEC’s website at www.sec.gov, discuss other risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release. We urge you to consider all of the risks, uncertainties and factors identified above or discussed in such reports carefully in evaluating the forward-looking statements in this press release.
| Last Trade: | US$7.46 |
| Daily Change: | 0.19 2.61 |
| Daily Volume: | 320,851 |
| Market Cap: | US$375.090M |
November 06, 2024 August 06, 2024 July 01, 2024 May 08, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
